Your session is about to expire
← Back to Search
Janus Kinase (JAK) Inhibitor
Tofacitinib for Chronic Granulomatous Disease
Phase 1 & 2
Waitlist Available
Led By Christa S Zerbe, M.D.
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Aged >=18 years
Be older than 18 years old
Must not have
Current use of inhaled tobacco products, vaping product, inhaled cannabis, or other illicit inhaled drugs
History of unprovoked deep vein thrombosis, pulmonary embolism, or other thrombotic events
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through day 120
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing tofacitinib, a pill that reduces inflammation, in adults with chronic granulomatous disease (CGD) who haven't responded to other treatments. The drug aims to calm the overactive immune system in these patients. Tofacitinib has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Who is the study for?
Adults over 18 with Chronic Granulomatous Disease (CGD) who've had little success with other treatments can join this trial. They must be part of NIH study #93-I-0119, not have severe kidney disease or infections like hepatitis B/C, HIV, or active EBV. Pregnant individuals and those using certain drugs are excluded.
What is being tested?
The trial is testing Tofacitinib's safety and effectiveness for treating CGD complications. Participants will reduce current CGD meds and take Tofacitinib pills twice daily for three months while undergoing health assessments, including blood tests and CT scans.
What are the potential side effects?
Tofacitinib may cause side effects such as increased risk of infections due to immune system suppression, potential liver issues indicated by blood test changes, possible kidney problems, and a higher chance of developing certain skin conditions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I currently use inhaled tobacco, vaping products, cannabis, or other illicit drugs.
Select...
I have had blood clots in my veins or lungs without a clear cause.
Select...
I am not allergic to tofacitinib, acyclovir, or valacyclovir.
Select...
I am taking aspirin or NSAIDs that cannot be stopped safely.
Select...
I am infected with hepatitis B, C, or HIV.
Select...
I have severe kidney disease.
Select...
I have had a gastrointestinal perforation in the past.
Select...
I am currently being treated for a serious infection.
Select...
I am currently unable to move around freely.
Select...
I have a history of heart failure.
Select...
I have had cancer before, but not skin cancer.
Select...
I have tuberculosis, whether active or not.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 through day 120
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through day 120
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of serious bacterial, mycobacterial, fungal, or viral infections defined as infections that require medical assessment or hospitalization.
Rate of AEs
Rate of infection.
+1 moreSecondary study objectives
CGD-related IBD: 1.Change in modified HBI. 2.Change in histopathological endoscopy.
Gene expression: 1.Change in IFN gene module enrichment score derived from whole blood RNA expression data.
Inflammatory lung disease: 1. Change in FEV1. 2. Change in DLCO. 3.Change in CT radiography. 4. Change in 6-minute walk.
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: XELJANZ (tofacitinib)Experimental Treatment1 Intervention
Tofacitinib is self-administered orally at 5 mg twice per day or 11 mg once per day for 3 months.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Chronic Granulomatous Disease (CGD) treatments often focus on enhancing immune response or reducing inflammation. Janus kinase (JAK) inhibitors like Tofacitinib block the JAK-STAT signaling pathway, crucial for producing inflammatory cytokines.
This helps reduce chronic inflammation and granuloma formation, improving immune function and reducing complications in CGD patients.
Role of Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Regulating Neutrophil Antifungal Activity and the Oxidative Burst During Respiratory Fungal Challenge.Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.A human in vitro granuloma model for the investigation of multinucleated giant cell and granuloma formation.
Role of Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Regulating Neutrophil Antifungal Activity and the Oxidative Burst During Respiratory Fungal Challenge.Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.A human in vitro granuloma model for the investigation of multinucleated giant cell and granuloma formation.
Find a Location
Who is running the clinical trial?
National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,336 Previous Clinical Trials
5,392,814 Total Patients Enrolled
Christa S Zerbe, M.D.Principal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)
7 Previous Clinical Trials
592 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your blood tests show very high levels of certain enzymes, or very low levels of white blood cells.I do not have any health conditions that could affect the study's treatment evaluation.I currently use inhaled tobacco, vaping products, cannabis, or other illicit drugs.I am 18 years old or older.I have IBD, lung, or skin disease related to CGD diagnosed through endoscopy, imaging, or PFTs.I am using a strong CYP3A4 inducer and cannot stop it 14 days before starting tofacitinib.I have had blood clots in my veins or lungs without a clear cause.I am not allergic to tofacitinib, acyclovir, or valacyclovir.I am taking aspirin or NSAIDs that cannot be stopped safely.You currently have an active EBV infection.I am infected with hepatitis B, C, or HIV.I have severe kidney disease.You have had a disease that affects your connective tissues in the past.I have had a gastrointestinal perforation in the past.I am currently being treated for a serious infection.I am currently unable to move around freely.I have a history of heart failure.I have had cancer before, but not skin cancer.I have tuberculosis, whether active or not.
Research Study Groups:
This trial has the following groups:- Group 1: XELJANZ (tofacitinib)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.